Tobias Hohl, MD, PhD

Chief

Share
Print
Share
Print
Pictured: Dr. Tobias Hohl

Education

Duke University

Tobias, a native of Switzerland, moved to the US in 1990 to attend college at Duke University.  After undergraduate research stints at the Biocenter in Basel (with Jeff Schatz) and at the Whitehead institute (with Harvey Lodish), Tobias moved to New York in 1993 to enroll in the Tri-Institutional MD-PhD Program. As graduate student, Tobias studied the mechanisms of SNARE complex formation and disassembly in Jim Rothman’s lab and explored the potential of genetically encoded reporters of biological function under Gero Miesenböck. Tobias went on to train in internal medicine and infectious diseases and joined Eric Pamer’s lab for post-doctoral studies in fungal pathogenesis and immunology. In 2009, Tobias started his own laboratory-based research program at Fred Hutchinson Cancer Research Center. He returned to Memorial Sloan Kettering in 2013 where he is now the Chief of the Infectious Disease Service. Outside the lab, Tobias loves to explore New York on foot and on the bicycle; his current favorite show is Billions.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Tobias Hohl discloses the following relationships and financial interests:

  • Merck & Co Inc.
    Provision of Services
  • Partner Therapeutics, Inc.
    Provision of Services
  • Portola Pharmaceuticals
    Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures